MDK and neoplasm: A promising human MDK blockade system has already been established in vitro using prostate cancer xenografts, where synthetic siRNA in combination with the chemotherapeutic paclitaxel (PTX) affects tumor cell proliferation, apoptosis, and angiogenesis (132).